Korea University Background
There is a need for a new treatment method for existing methods of inhibiting the progress of hepatic fibrosis. The existing methods of inhibiting the progress of hepatic fibrosis are known such as elimination of cause of hepatocyte damage, relief of inflammation in hepatic tissue, inhibition of activation of hepatic fibrosis factors, inhibition of activation of active hepatic stellate cell, and decomposition of extracellular matrix, etc. However, a gene therapy and therapy methods using stem cell are unknown.
Composition for prevention or treatment of hepatic fibrosis containing exosome or ribonucleic acid derived therefrom
Exosome is derived from mesenchymal stem cells(MSC) or hepatocyte-like cells(HLC) ().
Ribonucleic acid derived from exosome was selected among miR-136, miR-199a, miR-409,miR-410 and miR-432.
The present technology contains exosome or ribonucleic acid derived from exosome.
The hepatic fibrosis is caused by chronic liver damage and induced by a network of extracellular matrix and fibrosis-related signal transduction mechanism.
There is TGF-β(transforming growth factor β) signal transduction mechanism in this signal transduction mechanism.
The exosome of this technology or ribonucleic acid derived therefrom reduce the expression of α-SMA that is expressed in hepatic stellate cell activated by TGF-β signal transduction mechanism.
Verification of anti-hepatic fibrosis efficacy in chronic hepatic fibrosis animal model
Results of sirius red staining and immunofluorescent staining are performed ().
It is confirmed that deposition of collagen in hepatic tissue is inhibited.
It is confirmed that the number of active hepatic stellate cells(α-SMA) that are the main cause of macrophage(R4/80)and hepatic fibrosis is reduced.
Inhibition of hepatic fibrosis by reducing expression of α-SMA
Hepatic fibrosis is inhibited by reducing expression of α- SMA that is expressed in hepatic stellate cell.
The progress of hepatic fibrosis is inhibited by inhibiting deposition of collagen in hepatic tissue.
This technology can be used as various biomedicines such as prevention and treatment of liver-related diseases and diagnosis, prevention, treatment, drug carrier, etc. of diseases such as cancer.
The global market for exosome research products is expected to reach from $91 million in 2019 to $264 million in 2024 according to an annual average growth rate of23.8%. It is expected that the market will be led by increased investment in life science research, global cancer induction rate and interest in exosome-based diagnosis.
– Built in laboratory environment.